Lymphocyte Activation Gene-3 (LAG-3) Negatively Regulates Environmentally-Induced Autoimmunity

Vibha Jha1, Creg J. Workman3, Tracy L. McGaha2, Liping Li1, Jaya Vas1, Dario A. A. Vignali3, Marc Monestier1*

1 Temple Autoimmunity Center and Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania, United States of America, 2 Department of Medicine, Section of Rheumatology, Temple University School of Medicine, Philadelphia, Pennsylvania, United States of America, 3 Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

Abstract

Environmental factors including drugs, mineral oils and heavy metals such as lead, gold and mercury are triggers of autoimmune diseases in animal models or even in occupationally exposed humans. After exposure to subtoxic levels of mercury (Hg), genetically susceptible strains of mice develop an autoimmune disease characterized by the production of highly specific anti-nucleolar autoantibodies, hyperglobulinemia and nephritis. However, mice can be tolerated to the disease by a single low dose administration of Hg. Lymphocyte Activation Gene-3 (LAG-3) is a CD4-related, MHC-class II binding molecule expressed on activated T cells and NK cells which maintains lymphocyte homeostatic balance via various inhibitory mechanisms. In our model, administration of anti-LAG-3 monoclonal antibody broke tolerance to Hg resulting in autoantibody production and an increase in serum IgE level. In addition, LAG-3-deficient B6.SJL mice not only had increased susceptibility to Hg-induced autoimmunity but were also unresponsive to tolerance induction. Conversely, adoptive transfer of wild-type CD4 T cells was able to partially rescue LAG-3-deficient mice from the autoimmune disease. Further, in LAG-3-deficient mice, mercury elicited higher amounts of IL-6, IL-4 and IFN-γ cytokines known to play a critical role in mercury-induced autoimmunity. Therefore, we conclude that LAG-3 exerts an important regulatory effect on autoimmunity elicited by a common environmental pollutant.

Introduction

Mercury (Hg) is a hazardous environmental contaminant. Several studies report that mercury exposure is associated with autoimmune dysfunction in occupationally-exposed humans [1–5]. In susceptible H2B mice such as A.SW or B6.SJL, subtoxic levels of HgCl2 induce an autoimmune dysfunction characterized by glomerulonephritis, production of antinuclear autoantibodies (ANA) and hypergammaglobulinemia (especially pronounced for IgE and IgG1) [6–11]. The increase in polyclonal immunoglobulins peaks 2 weeks after the first HgCl2 injection and returns to normal levels by week 4. The production of antigen-specific ANA starts at week 2 and continues to increase for about 4 to 6 weeks. Susceptible animals can however be tolerated to Hg. When A.SW mice receive a single low dose injection of HgCl2, they become resistant to a subsequent standard challenge of HgCl2 [12]. Administration of Hg can also potentiate disease in other mouse models of autoimmunity [13,14]. The mechanisms by which mercury can induce disease are not fully understood [7] although interference with signal transduction pathways in T cells might play an important role [15].

Lymphocyte activation gene-3 (LAG-3) is a type I transmembrane protein expressed on activated CD4+ and CD8+ T cells, a subset of γδ T cells, NK cells and regulatory cells (Tregs) [16,17]. LAG-3 has a genomic proximity to CD4 [18] and like CD4, it binds to MHC-II [17,19] albeit with a higher affinity [20]. The functions of LAG-3 are dependent on its interaction with MHC-II and a conserved KIEELE motif present in its cytoplasmic domain [16].

LAG-3-deficient mice do not exhibit any adverse phenotype [16]. In fact, the initial analysis of LAG3−/− did not reveal a defect in T cell function and no gross T cell abnormalities are present [21,22]. However, LAG-3-deficient T cells undergo an increase in expansion as compared to the wild-type T cells in a lymphopenic environment. Additionally, Lag-3−/− mice have increased numbers of lymphocytes that do not normally express LAG-3 such as B cells, granulocytes, macrophages and DCs indicating that deregulation of LAG-deficient T cells influences the expansion of cell types from other lineages [23].

A real-time PCR study indicates that antigen-specific CD4+ T cells of regulatory phenotype have higher expression of LAG-3 as compared to the antigen-specific effector CD4+ T cells. Both natural and induced Tregs lacking LAG-3 in vivo are defective in their suppressive activities [22]. Also, ectopic expression of LAG-3 imparts regulatory phenotype to CD4+CD25− T cells [23,24]. In addition, Liang et al. have reported that LAG-3 on Tregs can engage MHC class II on DCs and induce an ITAM-mediated...
inhibitory signaling pathway to suppress DC maturation and function [25].

Regulation of homeostatic balance and maintenance of tolerance are two critical immunological processes that prevent the development of autoimmune diseases. To understand the impact of homeostatic balance on environmentally-induced autoimmunity, we sought to investigate the role of LAG-3 in mercury-induced autoimmunity. Our observations indicate that mice exposed to Hg have higher expression of LAG-3 on CD4+ T cells. Abrogation of LAG-3 functions, either by administering anti-LAG-3 monoclonal antibody or by genetic ablation of LAG-3, results in an increased susceptibility to mercury-induced autoimmunity. Thus our data indicate that LAG-3 plays an important role in the prevention of environmentally-induced autoimmunity.

Materials and Methods

Mice

A.SW/Snj (H2s) were obtained from Jackson Laboratories (Bar Harbor, ME). Lag-3−/− C57BL/6 (H2b) mice were described previously and were fully backcrossed onto the B6 background [22]. Lag-3−/− C57BL/6 mice were crossed with B6.SJL (H2s) mice to generate Lag-3−/− B6.SJL mice. Homozygosity for LAG-3 targeted deletion and for H2s was determined by PCR as described before [26,27]. All mice used for the experiments were at least 2 months old. Animals were sacrificed using a CO2 chamber.

Ethics Statement

We followed the regulations under all federal, state and local laws while using the animals. The experiments using animals were performed with approval and oversight of Temple University, School of Medicine Institutional Animal Care and Use Committee under protocol number 925.

Data Availability Statement

The authors confirm that data corresponding to the findings are completely available without restriction. All data are included in the manuscript.

Serum Collection

Mice were anesthetized using regulated levels of isoflurane and then bled once a week retro-orbitally for up to 4 weeks after the start of treatments. The blood samples were incubated at 37°C for

Figure 1. Exposure to Hg results in higher expression of LAG-3 on CD4+ T cells and in an increased amount of soluble LAG-3 in serum. (A) B6.SJL mice were left untreated or given 3 injections of HgCl2 s.c. on days 0, 2 and 4. Splenocytes were harvested on day 8 and analyzed by flow cytometry. Figure depicts a representative dot plot of total splenocytes gated for LAG-3+ CD4+ T cells. (B) Results are expressed as frequency of LAG-3+ CD4+ T cells in each group (n = 3 or 4). (C) A.SW mice were challenged with 3 injections of HgCl2 (30 μg/mouse) on days 0, 2 and 4. Concentration of soluble LAG-3 (sLAG-3) in serum was measured by ELISA (n = 4 or 5). Unpaired t test was used for statistical analysis where *indicates p < 0.05.

doi:10.1371/journal.pone.0104484.g001
45 minutes, followed by incubation at 4°C for 2 hours. Coagulated blood was removed using a wood applicator. Samples were then centrifuged at 8000 rpm for 5 minutes. The separated serum was transferred to 0.65 ml eppendorf tubes and stored at -20°C for future analysis.

HgCl₂ and antibody treatment

Mercury-induced autoimmunity was induced in groups of 5 or 6 mice according to a standard protocol by sub-cutaneous (s.c.) injections given on days 0, 2 and 4 (each injection consisted of 30 μg HgCl₂ in 100 μl of sterile PBS). Tolerance was induced by a single intraperitoneal (i.p.) injection of 3 μg of HgCl₂ in 300 μl of sterile PBS given on day -7 [12]. In addition to HgCl₂, some groups of mice also received i.p. injections of blocking anti-LAG-3 monoclonal antibody [28]. An irrelevant rat IgG was used as control. Antibodies were administered in 300 μl of sterile PBS.

ANOXA Immunofluorescence

Serum IgG1 and IgG2a ANoA (the main isotypes produced during mercury-induced autoimmunity) levels were determined by indirect immunofluorescence (IF) as described previously [29]. Sera diluted in PBN (PBS containing 1% BSA and 0.02% sodium azide) were incubated with HEp-2 slides (Antibodies, Inc, Davis, CA) for 30 minutes and ANoA were detected with FITC-conjugated goat anti-mouse IgG1 or IgG2a antibodies (Southern Biotechnology Associates, Birmingham, AL). The inverse of the highest serum dilution at which nucleolar fluorescence could be detected was defined as the ANoA titer.

ELISA for serum Ig

Total serum IgG1 and IgE levels were detected using a sandwich ELISA as described previously [29]. Briefly, 96 well polystyrene microtiter plates (Greiner Bio-one, Frickenhausen, Germany) were coated with goat anti-mouse Ig κ (Southern Biotechnology Associates, Birmingham, AL) or rat anti-mouse IgE (Clone R35-72, BD Pharmingen, San Diego, CA). Plates were blocked for 1 hour at room temperature (RT). Sera samples diluted 1 in 50,000 for IgG1 or 1 in 100 for IgE were added and incubated at RT. IgG1 was detected using alkaline phosphatase (AP)-coupled goat anti-mouse IgG1 (Southern Biotechnology Associates, Birmingham, AL). IgE was detected using biotinylated rat anti-mouse IgE (Clone, R35-72, BD Pharmingen, San Diego, CA). Antibody levels in the samples were extrapolated from a standard curve generated using varying concentrations (3.15–400 μg/ml) of
Figure 3. A short course of HgCl₂ injections is sufficient to induce mercury-induced autoimmunity in LAG-3-deficient B6.SJL mice. (A) Wild-type or Lag-3⁻/⁻ B6.SJL mice were challenged with HgCl₂ (30 µg/mouse s.c.) on days 0, 2 and 4. Serum was analyzed by ELISA to determine IgG1 and IgE polyclonal antibodies and ANoA titers were measured by IF assay (n = 5 or 6). (B) Kidneys of mice from this experiment were harvested after 4 weeks, sectioned and stained with goat anti-mouse IgG-FITC to detect IgG deposit. The extent of kidney disease was scored depending on the amount and intensity of IgG staining as described in details in Material and Method section. To determine statistical significance between the groups of fig. 2A and 2B two way ANOVA was used where *indicates \( p<0.05 \), **indicates \( p<0.005 \) and ***indicates \( p<0.0001 \).

doi:10.1371/journal.pone.0104484.g003

Figure 4. LAG-3-deficient mice cannot be tolerized to mercury. Wild-type or LAG-3-deficient mice were given a tolerogenic dose of HgCl₂ (3 µg/mouse given i.p.) on day -7. Mice were then exposed to 3 injections of HgCl₂ (30 µg/mouse given s.c) on days 0, 2 and 4. Serum Ig were measured by ELISA and ANoA titers were determined by IF assay (n = 5 or 6). To determine statistical significance between the groups two way ANOVA was used where *indicates \( p<0.05 \).

doi:10.1371/journal.pone.0104484.g004
ASWU1 (IgG1) previously purified in our laboratory [30] or purified mouse IgE (IgE-3) (BD Biosciences, San Jose, CA).

Cytokine ELISA

For cytokine ELISA, splenocytes were cultured in complete RPMI 1640 medium in 24 well plates coated with 3 μg/ml of anti-mouse CD3 and 2 μg/ml of anti-mouse CD28. Supernatants from cultured cells were collected at different time points to perform cytokine ELISA. Total IL-4, IL-6 and IFN-γ were measured by sandwich ELISA using reagents (recombinant mouse cytokine, anti-cytokine antibodies and biotinylated anti-cytokine antibodies) purchased from BD Pharmingen (San Diego, CA).

ELISA for soluble LAG-3

This ELISA was performed as described earlier [31].

Detection of immune complex deposits in kidney

Four weeks after the first HgCl₂ injection, kidneys were harvested from mice and embedded in Tissue-Tek OCT compound (Sakura, Torrance, CA) and snap-frozen on dry ice. A cryostat microtome was used to cut 4 μm sections. The sections were air dried, fixed with cold acetone and stained with goat anti-mouse IgG FITC (Southern Biotechnology Associates, Birmingham, AL) to detect IgG deposits. Glomerulonephritis was scored in a blinded fashion using 1–4 scale based on the percentage of glomeruli affected. The grading scale was 0 = no glomerulonephritis, 1+ ≤15%, 2+ 16–40%, 3+ 41–70%, and 4+ >70% of glomeruli affected. The lesions graded included thickening of the mesangium, noticeable increases in both mesangial and glomerular cellularity with/without superimposed inflammatory exudates and capsular adhesions, glomerulosclerosis, and cast formation. Scoring was performed on at least 200 glomeruli in a 40× field per kidney [32]. Immune complex deposition in kidneys was quantified by blinded observers and arbitrarily scored from 0 to 4 dependent on the intensity and amount of the anti-IgG staining in the glomeruli [32].

Flow Cytometry

To detect CD4⁺ T cells expressing LAG-3, splenocytes were subjected to RBC lysis and then stained with PE-conjugated anti-LAG-3 monoclonal antibody and FITC-labeled rat anti-mouse CD4 (BD Biosciences, San Jose, CA). LAG-3⁻/⁻ mice and RBC lysis was carried out using 0.164 M NH₄Cl. Cells were then stained with FITC-labeled rat anti-mouse CD4 (BD Biosciences, San Jose, CA). CD4⁺ T cells were sorted using a DakoCytomation...
MoFlo (DakoCytomation, Inc., Fort Collins, CO). Flow cytometry data were analyzed using FlowJo software (Tree Star, Ashland, OR).

Statistical methods

Graph Pad prism software was used to generate figures and perform statistical analyses. The method of statistical analysis used for each experiment is described in the corresponding figure legend.

Results

Exposure to Hg results in higher expression of LAG-3 on T cells and in an increased amount of soluble LAG-3 in serum

Exposure of susceptible strains of mice to subtoxic levels of mercury induces proliferation and activation of CD4+ T cells [33,34]. Because LAG-3 is expressed on activated T cells, we decided to investigate the effect of HgCl2 treatment on the expression of LAG-3. B6.SJL mice were either given three injections of HgCl2 on days 0, 2 and 4 or were left untreated. On day 8 splenocytes were stained with anti-CD4 and anti-LAG-3 monoclonal antibodies. Expression of LAG-3 on CD4+ T cells is shown in Fig. 1A and Fig. 1B. Exposure of mice to HgCl2 resulted in a two-fold increase in the percentage of CD4+ cells expressing LAG-3.

LAG-3 undergoes proteolytic cleavage by two metalloproteases to release a 54 KDa molecule called soluble LAG-3 (sLAG-3) which contains all of its extracellular domains [31,35]. Both in vitro and in vivo T cell activation results in an increase in the production of sLAG-3 [31]. Release of sLAG-3 is essential for proliferation of T cells and inactivation of this process results in inhibition of T cell multiplication and cytokine production [34]. This prompted us to check the level of serum sLAG-3 in mice challenged with HgCl2. A.SW mice received 3 injections of HgCl2 on days 0, 2 and 4. As depicted in Fig. 1C, the serum sLAG-3 concentration was 1.42 µg/ml after one week of Hg treatment versus 0.75 µg/ml in the untreated group. These experiments showed that exposure of mice to HgCl2 causes an increase in LAG-3+ CD4+ T cells and in the concentration of sLAG-3 in serum thus suggesting a possible role for LAG-3 in the T cell-mediated immune response to mercury.

LAG-3-deficient B6.SJL mice display an increased susceptibility to mercury-induced autoimmunity

B6.SJL mouse strain is congenic to C57BL/6 which possesses the Hg-susceptible H2s haplotype instead of the original H2d. This strain allows for cross-breeding of various targeted mutations which are typically present on the same B6 background. We thus evaluated mercury-induced autoimmunity in LAG-3-deficient B6.SJL mice. The LAG-3 mutation was bred onto B6.SJL mice expressing the susceptible H2s MHC haplotype. Wild-type or Lag-3−/− B6.SJL mice were given 3 s.c. injections of HgCl2 per week for 4 weeks up to a total of 12 injections. As shown in Fig. 2A, the Lag-3−/− B6.SJL mice had significantly higher levels of both serum IgG1 and IgE antibodies on day 14 and they developed higher titers of IgG1 and IgG2a ANoA. The wild-type B6.SJL mice displayed a milder disease with low levels of serum polyclonal IgG1, IgE and lower titers of ANoA as compared to Lag-3−/− mice. Since deposition of immune complexes in kidneys takes place during Hg-induced autoimmune disease, we performed immunofluorescence staining of kidney sections with anti-IgG FITC. The staining revealed that the Lag-3−/− mice had significantly increased immune complex deposits in their kidneys and the...
cumulative disease score was higher in Lag-3−/− mice as compared to the wild-type (Fig. 2B).

A short course of HgCl2 injections is sufficient to induce mercury-induced autoimmune disease in LAG-3-deficient B6.SJL mice

Unlike A.SW mice which are highly susceptible to Hg-induced autoimmunity, B6.SJL mice are moderately susceptible to Hg and develop mild manifestations if they receive only 3 injections of HgCl2. Hence, we hypothesized that genetic ablation of LAG-3 in B6.SJL mice would increase the susceptibility to a course of 3 injections of HgCl2. Therefore, Lag-3−/− or wild-type B6.SJL mice were given a challenge dose of HgCl2 on days 0, 2 and 4. We observed that Lag-3−/− mice developed a greater concentration of serum IgG1 and IgE immunoglobulins than the wild-type controls although the differences did not reach statistical significance. However, LAG-3-deficient mice exhibited a significantly higher titer of ANoA of both IgG1 and IgG2a isotypes, while the wild-type mice had barely detectable titers of ANoA (Fig. 3A). Likewise, Lag-3−/− mice had increased amounts of renal immune complex deposits relative to the wild-type mice (Fig. 3B).

LAG-3-deficient mice cannot be tolerized to mercury

In previous studies we showed that Hg-susceptible mice can be tolerized via a single low-dose injection of HgCl2 [10]. Therefore, we wanted to ascertain whether LAG-3-deficient B6.SJL mice could be tolerized to Hg as well. We gave a tolerogenic dose of HgCl2 (3 μg/mouse) to Lag-3−/− or wild-type B6.SJL mice 1 week before they were challenged with 3 s.c. injections of HgCl2 on days 0, 2 and 4. As displayed in Fig. 4, we observed that tolerance was established in wild-type mice since their levels of IgG1 and IgE immunoglobulins did not increase and they produced very low titers of IgG1 ANoA after Hg challenge. In contrast the Lag-3−/− mice exhibited increased amounts of both IgG1 and IgE antibodies and they responded with high titers of IgG1 ANoA. Hence, absence of LAG-3-mediated signaling events leads to abrogation of tolerance induction by a single low dose of HgCl2.

Anti-LAG-3 monoclonal antibody breaks established tolerance to mercury-induced autoimmunity

We used a LAG-3-specific monoclonal antibody (mAb) to block the functions of LAG-3 in A.SW mice to confirm whether inhibition of LAG-3 functions interferes with tolerance induction in susceptible mice and to rule out the possibility of a
developmental defect due to LAG-3-deficiency. Moreover, the use of A.SW mice allowed us to monitor the effects of LAG-3 inactivation in mice with a genetic background different from B6.SJL. In mice that were previously tolerized to Hg, concomitant administration of anti-LAG-3 with HgCl₂ challenge resulted in a loss of tolerance manifested by increased serum IgG1 and IgE levels and greater ANoA titers than in mice receiving control rat IgG (Fig. 5). Therefore, these data are in agreement with the experimental results obtained with LAG-3-deficient animals.

LAG-3-deficient mice produced higher amounts of cytokine following mercury treatment

The previous experiments show that LAG-3 can modulate the regulation of Hg-induced autoimmunity. To investigate further the mechanisms by which LAG-3 influences the autoimmune disease, we compared the cytokine profile of LAG-3-deficient and wild-type B6.SJL mice which received 3 s.c. injections of HgCl₂ on days 0, 2 and 4 or were left untreated. Splenocytes were harvested on day 8 and stimulated with anti-CD3 and anti-CD28 antibodies and cytokines in the supernatant were measured after 3 days. The Lag-3-/- mice exposed to HgCl₂ produced significantly higher concentrations of IFN-γ, IL-4 and IL-6 as compared to both untreated Lag-3-/- mice and wild-type mice challenged with HgCl₂ (Fig. 6).

Transfer of wild-type CD4⁺ T cells decreases autoimmunity in LAG-3-deficient mice

Although LAG-3 is expressed on various cell types, CD4⁺ T cells appear to mediate most of its regulatory effects. We therefore hypothesized that transfer of wild-type CD4⁺ T cells might correct the increased susceptibility to autoimmunity in Lag-3-/- mice (Fig. 7). In this experiment, Lag-3-/- mice received either 4×10⁶ wild-type CD4⁺ T cells or 4×10⁶ Lag-3-/- CD4⁺ T cells and were challenged 2 days later with a standard course of 3 HgCl₂ injections. The wild-type CD4⁺ T cells were able to prevent the induction of autoimmunity as manifested by a significant reduction in titers of IgG1 and IgG2a ANoA following HG challenge. In addition, serum IgG1 and IgE levels were lower in mice that received wild-type CD4⁺ T cells as compared to the mice that received Lag-3-/- CD4⁺ T cells, although the levels did not reach statistical significance. Therefore, wild-type CD4⁺ T cells can partially correct the increased autoimmune susceptibility of LAG-3-deficient mice.

Discussion

The studies in this paper indicate that LAG-3 plays a critical role in decreasing the manifestations of Hg-induced autoimmunity. In the absence of LAG-3-mediated functions, B6.SJL mice that are normally moderately susceptible to the disease become more sensitive to Hg. LAG-3 also plays an essential role in both the induction and maintenance of tolerance to Hg in susceptible animals that can be established via administration of a single low dose of Hg. Hg elicits higher cytokine production in LAG-3-deficient animals and adoptive transfer of wild-type CD4⁺ T cells can partially rescue LAG-3-deficient B6.SJL mice from Hg-induced autoimmunity.

Our observations support previous studies illustrating that LAG-3 exert a regulatory role upon the immune system. T cell exhaustion occurs during chronic viral infections and results in lack of viral control due to ineffective effector functions of the exhausted antigen-specific CD8⁺ T cells [36]. Expression of LAG-3 along with other inhibitory receptors such as PD-1 and CTLA-4 is upregulated on exhausted CD8⁺ T cells during chronic LCMV infection in mice [37,38]. Dual treatment of mice with blocking antibodies specific for LAG-3 and PD-L1 during chronic LCMV infection resulted in an improved CD8⁺ T cell response combined with a greater decrease in viral load [39]. In C3HA mice which express hemagglutinin (HA) as self antigen, adoptively transferred HA-specific transgenic CD8⁺ T cells [39] or HA-specific CD4⁺ T cells [6.5 T cells] [40] are anergic and show increased expression of LAG-3. Blocking of LAG-3-MHC-II interactions with anti-LAG-3 antibody result in cellular expansion and increased IFN-γ production by clone 4 T cells [39]. Likewise, transfer of Lag-3⁻/⁻/6.5 T cells causes loss of tolerance and death of recipient C3HA mice [40]. In addition, anergic 6.5 T cells have a higher expression of Foxp3 along with LAG-3 suggesting that LAG-3+ T cells acquire a regulatory T cell phenotype [24,40]. Taken together, these studies indicate that LAG-3 plays an inhibitory role on immune functions that facilitate persistent viral infections, but allow for the maintenance of self-tolerance. Our current studies demonstrate that mercury-induced autoimmune disease in LAG-3-deficient mice can be partially prevented by adoptive transfer of WT CD4⁺ T cells, thereby suggesting that LAG-3+ T cells are essential for maintenance of tolerance toward mercury.

Our present study shows that LAG-3 exerts a critical regulatory role in a model of induced experimental autoimmunity. Our results indicate some possible mechanisms by which LAG-3 may exert its effects. Hg-treated LAG-3-deficient B6.SJL mice produced significantly higher amounts of IFN-γ, IL-4 and IL-6 as compared to naive LAG-3-deficient mice or wild-type mice exposed to HgCl₂. This is significant since all three cytokines are known to play a critical role in the pathogenesis of Hg-induced autoimmune disease. IFN-γ is responsible for the loss of self-tolerance in this model as IFN-γ-deficient mice fail to produce antineutrophil antibodies in response to Hg [41]. Abrogation of IL-4 functions either by genetic deletion of IL-4 [41,42] or by *in vivo* administration of a blocking anti-IL-4 monoclonal antibody [43,44] results in a significant decrease in Hg-induced IgG1 and IgE polyclonal activation [40,41 and 42]. Likewise, IL-6-deficient mice show a decrease in polyclonal activation following mercury treatment [45,46]. In addition, our results indicate that LAG-3 expression on CD4⁺ T cells is critical for its regulatory role in Hg-induced autoimmunity since transfer of normal CD4⁺ T cells to LAG-3-deficient mice partially corrects their phenotype.

CD4⁺ T cells that possess a regulatory phenotype display a higher expression of LAG-3 [24,40,47]. Tregs deficient in LAG-3 molecule are unable to optimally suppress the autoreactive T cells, whereas ectopic expression of LAG-3 imparts regulatory phenotype to CD4⁺CD25⁺ T cells [17]. Several studies report that Tregs modulate dendritic cell (DC) function and maturation [48-50] and Liang et al. have suggested that LAG-3 mediates its effects via DCs [25]. This study showed that LAG-3 expressed on Tregs interacts with MHG-II on DCs and this interaction causes suppression of DC maturation and DC immunostimulatory capacity [25]. The down-regulation of DC function and maturation would then interfere with its ability to stimulate autoreactive effector T cells. Absence of LAG-3 would thus abrogate this Treg-mediated inhibition of DC maturation, eventually culminating in loss of tolerance toward self-antigens. Our preliminary observations suggest that Tregs play an important role in the regulation of Hg-induced autoimmunity [12]. Thus, LAG-3 may mediate its effects via Tregs in preventing autoimmune reactions triggered by Hg.

Although LAG-3 is predominantly expressed on activated T cells and NK cells, a single study reported that B cells can express LAG-3 in a T cell dependent manner [51]. The expression of
LAG-3 is limited on activated B cells and it is induced by T cells, thus B cells activated via various other stimuli (bacterial LPS, CD40+ IL-4) do not express LAG-3 [49]. Although both the expression and putative function of LAG-3 on B cells have to be confirmed, its role could be inhibitory as well and could represent an additional regulatory element in Hg-induced autoimmunity, a model which manifests itself essentially via humoral manifestations.

It was recently reported that LAG-3 is constitutively expressed in large amounts on plasmacytoid DCs (pDCs) and that it negatively regulates their activation [52]. CpG-activated Lag-3−/− pDCs proliferate faster than their wild-type counterparts, although they do not differ in terms of surface molecule expression and cytokine production. Functional studies indicate that LAG-3 on pDCs not only controls the proliferation of pDCs themselves but also regulates the T cell homeostasis [50]. This study suggests that LAG-3 expression on both pDCs and T cells plays a reciprocal regulatory role on the opposite cell type. Although the role of pDCs in Hg-induced autoimmunity remains to be identified, several studies have shown that pDCs in their immature state or in certain anatomical sites have tolerogenic properties [53–55]. It is therefore possible that inhibitory effects of LAG-3 on pDCs might have contributed to the observations in the present study.

Taken together, our observations indicate that LAG-3 has an important inhibitory role in the induction and maintenance of tolerance during the course of an induced experimental autoimmune disease. Our study adds autoimmunity to the list of pathological situations such as infections, cancer, and transplantation where LAG-3 can inhibit immune responses. It also suggests that the LAG-3 pathway may represent one of the mechanisms by which tolerance is maintained during autoimmune disease and that restoring or strengthening this pathway could represent a novel therapeutic avenue.

Author Contributions
Conceived and designed the experiments: VJ MM. Performed the experiments: VJ CJW JV LL. Analyzed the data: VJ TLM MM. Contributed reagents/materials/analysis tools: CJW JV DAAV. Wrote the paper: VJ MM.

References
1. Schiraldi M, Monestier M (2009) How can a chemical element elicit complex immunopathology? Lessons from mercury-induced autoimmunity. Trends Immunol 30: 502–509.
2. Mosczynski P, Slowski S, Rukowski J, Bem S, Jaksz-Stoga D (1995) Lympocytes, T and NK, cells in men occupationally exposed to mercury vapours. Int J Environmental Med Environ Health 6: 49–56.
3. Lauwersy R, Bernard A, Roels H, Buchet JP, Gennari JP, et al. (1983) Antilaminin antibodies in workers exposed to mercury vapour. Toxicol Letters 17: 113–116.
4. Arnett FC, Revell JD, Goldstein R, Pollard KM, et al. (1996) Autoantibodies to fibrin/fibrinogen in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 39: 1151–1160.
5. Silbergeld EK, Silva IA, Nyland JF (2005) Mercury and autoimmunity: implications for occupational and environmental health. Toxicol Appl Pharmacol 207: 292–299.
6. Hanley GA, Schiltenauer J, Sobel ES (1998) Resistance to HgCl2-induced autoimmunity in haplotype-heterozygous mice is an intrinsic property of B cells. J Immunol 161: 1778–1785.
7. Vas J, Monestier M (2000) Immunology of mercury. Ann N Y Acad Sci 1143: 240–257.
8. Pollard KM, Hultman P, Kono DH (2005) Immunology and genetics of induced systemic autoimmunity. Autoimmunity Rev 4: 282–298.
9. Robinson CJ, White HJ, Rose NR (1997) Murine strain differences in response to mercuric chloride: antigenic antibodies production does not correlate with renal immune complex deposition. Clin Immunol Immunopathol 65: 240–267.
10. Hultman P, Bell JL, Eacrest S, Pollard KM (1992) Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in infected, congenic, and intra-H-2 recombinant strains. Clin Immunol Immunopathol 63: 98–109.
11. Hanley GA, Schiltenauer J, Sobel ES (1997) Class II haplotype differentially regulates immune response in HgCl2-treated mice. Clin Immunol Immunopath 84: 328–337.
12. Vas J, Mattner J, Richardson S, Ndonye R, Monestier M, et al. (2008) Regulatory roles for NKT cell ligands in environmentally induced autoimmunity. J Immunol 181: 6779–6808.
13. Via CS, Nguyen P, Nicaudov F, Papadimitriou J, Silbergeld EK, et al. (2003) Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus. Environ Health Perspect 111: 1273–1277.
14. Pollard KM, Pearson DL, Hultman P, Deane TN, Kono DH, et al. (2001) Xenotropic activation of allopathic systemic autoimmunity in lupus-prone mice. Environ Health Perspect 109: 27–33.
15. Zienba SE, Menard SL, McCall MJ Jr, Rosepenig AJ (2009) T-cell receptor signaling is mediated by transient Lck activity, which is inhibited by inorganic mercury. FASEB J 23: 1663–1671.
16. Workman CJ, Dugger KJ, Vignali DAA (2002) Cutting Edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol 169: 5392–5395.
17. Huard B, Gaulard P, Faure F, Herend T, Triebel F (1994) Cellular expression and distribution of the human LAG-3-encoded protein, an MHC-II ligand. Immunogenetics 39: 213–217.
18. Bruniquel D, Borie N, Triebel F (1997) Genomic organization of human LAG-3/CD14 locus. Immunogenetics 47: 96–98.
19. Bairesser H, Huard B, Miossec C, Jitsukawa S, Paulet-Tommeau D, et al. (1992) Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 176: 327–337.
20. Bertrand H, Prigent P, Tournier M, Bruniquel D, Triebel F (1995) CD4-major histocompatibility complex class II interaction analysed with CD4+ and lymphocyte activation gene-3 (LAG-3)–Ig fusion proteins. Eur J Immunol 25: 2718–2721.
21. Workman C, Vignali D (2005) The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 33: 970–979.
22. Miyazaki T, Dievec B, Benoit C, Mathis D (1996) Independent modes of natural killer killing distinguished in mice lacking LAG3. Science 272: 403–408.
23. Workman C, Vignali DAA (2005) Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 174: 688–693.
24. Huang CT, Workman J, Fries D, Pan X, Vignali DAA, et al. (2006) Role of LAG-3 in regulatory T cells. Immunity 21: 503–513.
25. Liang B, Workman C, Lee J, Chew C, Clunes R, et al. (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180: 5916–5926.
26. Triebel F, Jitsukawa S, Bairesser B, Rothen-Rutishauser B, Herend T, et al. (1999) LAG-3, a novel lymphocyte activation gene 3 closely related to CD4. J Exp Med 191: 1393–1405.
27. Abhil/Valguer/ M, Hansson M, Moller G (2001) Genetic control of resistance to mercury-induced immune/autoimmune activation. Scand J Immunol 53: 190–197.
28. Workman CJ, Rice DS, Dugger KJ, Krischner C, Vignali DAA (2002) Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol 32: 2253–2263.
29. Bayraktosuce LM, Salgame P, Monestier M (1998) IL-2 down-regulates autoantibody production in mercury-induced autoimmunity. J Immunol 160: 1612–1617.
30. Monestier M, Lomzan MJ, Novick KE, Aris JP (1994) Molecular analysis of mercury-induced antinuclear antibodies in H-2H mice. J Immunol 152: 667–675.
31. Li N, Workman CJ, Martin SM, Vignali DAA (2004) Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3). CD223). J Immunol 173: 6006–6012.
32. McGaha TL, Karlsson MCI, Ravetch JV (2008) Fc{gamma}RIIB Deficiency Leads to Autoimmunity and a Defective Response to Apoptosis in Mrl-MpJ Mice. J Immunol 180: 5670–5679.
33. Pollard KM, Landberg GP (2001) The in vitro proliferation of murine lymphocytes to mercuric chloride is restricted to mature T cells and is interleukin 1 dependent. Int Immunopharmacol 1: 581–593.
34. Johansson U, Sander B, Hultman P (1997) Effects of the murine genotype on T cell activation and cytokine production in murine mercury-induced autoimmunity. J Autoimmun 10: 347–357.
35. Li N, Wang Y, Forbes K, Vignali KM, Vignali DAA, et al. (2007) Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 26: 494–504.
36. Shi H, Wherry EJ (2007) CD8 T-cell dysfunction during chronic viral infection. Curr Opin Immunol 19: 409–415.
37. Richter K, Agbemou O, Oseus A (2010) On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection. Int Immunol 22: 13–23.
38. Blackburn SD, Shin H, Haining WN, Zou T, Wherry EJ, et al. (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10: 29–37.
39. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Drake G, et al. (2007) LAG-3 regulates CD8+ T cell accumulation and effector function in murine self and tumor-tolerance systems. J Clin Invest 117: 3383–3392.
40. Zarek PE, Huang CT, Lutz ER, Kowalski J, Powell JD, et al. (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111: 251–259.
41. Kono DH, Balomenos D, Pearson DL, Park MS, Pollard KM, et al. (1998) The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-gamma and not Th1/Th2 imbalance. J Immunol 161: 254–260.
42. Bagresto LM, Salgame P, Monestier M (1998) Mercury-induced autoimmunity in the absence of interleukin-4. Clin Exp Immunol 114: 9–12.
43. Ochel M, Vohr HW, Pfeiffer C, Gleichmann E (1991) IL-4 is required for the IgE and IgG1 increase and IgG1 autoantibody formation in mice treated with mercuric chloride. J Immunol 146: 3006–3011.
44. Pollard KM, Hultman P, Kono DH (2003) Using single-gene deletions to identify checkpoints in the progression of systemic autoimmunity. Ann N Y Acad Sci 987: 236–239.
45. Martin P, Gloria M, Njuere F, Arias CF, Ardavin C, et al. (2002) Characterization of a new subpopulation of mouse CD8 alpha+B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100: 383–390.
46. Fallarino F, Grohmann U, Hwang KW, Orabona, Puccetti P, et al. (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4: 1206–1212.
47. Serra P, Amraani A, Yamanouchi J, Han B, Santamaria P, et al. (2003) CD40 ligation releases dendritic cells from the control of CD4+CD25+ regulatory T cells. Immunol 19: 877–889.
48. Houot R, Perrot I, Garcia E, Durand I, Lebecque S (2006) Human CD4+CD25+ high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 176: 5285–5290.
49. Kisielow M, Kisielow J, Capofrere-Sallani G, Karjalainen K (2005) Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol 35: 2081–2088.
50. Workman CJ, Wang Y, El Kaumi KC, Pardoll DM, Vignali DAA, et al. (2009) LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 182: 1815–1821.
51. Fallarino F, Asselin-Paturel C, Vacca C, Bianchi R, Puccetti P, et al. (2004) Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173: 3748–3754.
52. Martin P, Gloria M, Njuere F, Arias CF, Ardavin C, et al. (2002) Characterization of a new subpopulation of mouse CD8 alpha+B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100: 383–390.
53. Fallarino F, Asselin-Paturel C, Vacca C, Bianchi R, Puccetti P, et al. (2004) Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173: 3748–3754.